isomethyleugenol has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dostert, P; Maruyama, W; Nagatsu, T; Nakahara, D; Naoi, M; Niwa, T; Takahashi, A; Takeda, N; Tatematsu, A; Yoshizumi, H | 1 |
| Costall, B; Jenner, P; Marsden, CD; Naylor, R; Testa, B | 1 |
| Ansher, SS; Baker, JK; Cadet, JL; Jakoby, WB | 1 |
| Andrews, JS; de Boer, T; Gibson, S; Plate, R; Plaum, MJ; Rae, DR | 1 |
| Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A | 1 |
| Ramsden, DB; Williams, AC | 1 |
| Ali, SF; Charlton, CG; Jiao, Y; Lamango, NS; Lee, ES; Oriaku, ET; Schmued, L; Shepherd, KR; Soliman, KF | 1 |
| Bezard, E; Brotchie, JM; Fox, SH; Hallett, PJ; Lubin, FD; Nicholas, AP; Ravenscroft, P; Standaert, DG; Sweatt, JD; Vattem, P; Zhou, S | 1 |
| Charlton, CG; Dent, L; Griffin, B; King, J; Mackey, V; Muthian, G; Smith, ML | 1 |
1 review(s) available for isomethyleugenol and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methylation; Niacinamide; Parkinson Disease; Parkinson Disease, Secondary; Risk Factors; S-Adenosylmethionine | 2005 |
8 other study(ies) available for isomethyleugenol and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Endogenous synthesis of N-methylsalsolinol, an analogue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in rat brain during in vivo microdialysis with salsolinol, as demonstrated by gas chromatography-mass spectrometry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Gas Chromatography-Mass Spectrometry; Isoquinolines; Male; Methylation; Parkinson Disease; Perfusion; Rats; Rats, Wistar; Salsoline Alkaloids; Tetrahydroisoquinolines | 1992 |
Does an endogenous methylpyridinium analogue cause Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Chemical Phenomena; Chemistry; Humans; Methylation; Parkinson Disease; Pyridines | 1985 |
Role of N-methyltransferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines present in the environment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Brain; Environmental Pollutants; Humans; Macaca fascicularis; Methylation; Methyltransferases; Mice; Pyridines; Rabbits; Rats | 1986 |
Synthesis and muscarinic activities of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Analysis of Variance; Animals; Binding, Competitive; Disease Models, Animal; Dopamine Agents; Isotope Labeling; Male; Memory; Methylation; Mice; Miosis; Muscarinic Agonists; Muscarinic Antagonists; Mydriasis; Oxotremorine; Pirenzepine; Rabbits; Radioligand Assay; Rats; Rats, Wistar; Salivation; Structure-Activity Relationship; Vas Deferens | 1996 |
Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Cell Line; Cell Survival; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Harmaline; Harmine; Humans; Inhibitory Concentration 50; Kidney; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Methylation; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperazines | 2004 |
The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Dopamine; Drug Synergism; Herbicides; Homovanillic Acid; Humans; Male; Methylation; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neurotoxins; Paraquat | 2006 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity | 2008 |
Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Parkinsonian Disorders; Time Factors | 2014 |